New hope for prostate cancer: enzalutamide slows progression in asian men

NCT ID NCT02294461

Completed Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tested the drug enzalutamide in 395 Asian men with metastatic prostate cancer that had stopped responding to standard hormone therapy. Participants had not yet received chemotherapy. The study compared enzalutamide to a placebo to see if it could delay rises in PSA levels, a marker of cancer progression. The goal was to assess whether enzalutamide could help control the disease for a longer time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enzalutamide (Xtandi)
What this could lead to: If successful, enzalutamide could offer a new treatment option to delay cancer progression in men with metastatic prostate cancer who have not yet had chemotherapy.
What could go wrong: This trial is completed, but results may not apply to all populations. Enzalutamide can cause side effects like fatigue, high blood pressure, and falls. It controls the disease, not cures it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma Kennedy disease metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE METASTATIC PROSTATE CANCER

Contacts and locations

Locations

CN00102

Shanghai, China
CN00103

Beijing, China
CN00104

Beijing, China
CN00105

Shanghai, China
CN00106

Beijing, China
CN00107

Hangzhou, China
CN00108

Shanghai, China
CN00109

Wuhan, China
CN00110

Nanjing, China
CN00111

Beijing, China
CN00112

Beijing, China
CN00113

Shanghai, China
CN00114

Beijing, China
CN00115

Beijing, China
CN00117

Nanjing, China
CN00118

Wenzhou, China
CN00119

Suzhou, China
CN00121

Changsha, China
CN00124

Xi'an, China
CN00125

Tianjin, China
CN00126

Shanghai, China
CN00127

Beijing, China
HK00402

Hong Kong, Hong Kong
KR00201

Incheon, South Korea
KR00202

Seongnam-si, South Korea
KR00203

Daegu, South Korea
KR00204

Seoul, South Korea
KR00205

Busan, South Korea
KR00206

Seoul, South Korea
KR00207

Busan, South Korea
KR00208

Seoul, South Korea
KR00209

Seoul, South Korea
KR00210

Seoul, South Korea
KR00211

Seoul, South Korea
KR00212

Cheongju-si, South Korea
KR00213

Daejeon, South Korea
KR00214

Anyang, South Korea
KR00215

Seoul, South Korea
TW00301

Taipei, Taiwan
TW00302

Taichung, Taiwan
TW00303

Taichung, Taiwan
TW00304

Taipei, Taiwan
TW00305

Taoyuan County, Taiwan
TW00306

Taipei, Taiwan
TW00307

Tainan, Taiwan
TW00308

Tainan, Taiwan
TW00309

Kaohsiung City, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.